ACADIA Pharmaceuticals Inc. ACAD a biopharmaceutical company focused
on innovative treatments that address unmet medical needs in neurological and
related central nervous system disorders, today announced a private placement
equity financing pursuant to which ACADIA will receive gross proceeds of $86.4
million from the sale of its securities. Shares of ACADIA's common stock will
be sold at $4.43 per share, the closing market price on December 11, 2012. The
private placement is expected to close on December 17, 2012 and is subject to
the satisfaction of customary closing conditions.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in